KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Remote ischemic preconditioning versus sham-control for prevention of anastomotic leakage after resection for rectal cancer (RIPAL trial): a pilot randomized controlled, triple-blinded monocenter trial. PMID 38700747 · Int J Colorectal Dis · 2024-May-03 The study is a pilot randomized controlled trial in rectal cancer patients, but it is not Phase III/IIIb or Phase II/III. The intervention is remote ischemic preconditioning, a procedural intervention, not a drug. The primary endpoint is anastomotic leakage within 30 days, which is a binary outcome, not a time-to-event efficacy endpoint. No time-to-event outcomes like OS, PFS, DFS, EFS, RFS, TTP, or associated Kaplan-Meier curves or hazard ratios are reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial. PMID 38377176 · Oncologist · 2024-May-03 The record describes an ongoing Phase IIIb trial with interim results on safety and efficacy, including time-to-event endpoints (OS, PFS) for a drug combination. However, the randomized nature of the trial is not explicitly established in the provided abstract or metadata (e.g., the phrase 'randomized' is absent). The criteria require explicit establishment of all required criteria for eligibility, and randomization is a core requirement for inclusion as a definitive RCT. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide. PMID 38219019 · Neuro Oncol · 2024-May-03 The study is a randomized, human, oncology trial with a drug intervention (cilengitide), but it does not report a primary or key secondary time-to-event efficacy endpoint. The abstract describes an analysis of radiological progression patterns (pseudoprogression vs. true progression) using defined criteria, which is a descriptive/prognostic outcome, not a formal efficacy endpoint like OS or PFS. Therefore, it does not meet the eligibility criteria for a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. PMID 38206830 · Oncologist · 2024-May-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. PMID 38175669 · Oncologist · 2024-May-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001. PMID 38069666 · Neuro Oncol · 2024-May-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparison of Response First Technique with Reversal First Technique for Quality of Extubation in Patients Undergoing Transsphenoidal Pituitary Surgery: A Randomized Clinical Trial. PMID 39041968 · Neurol India · 2024-May-01 The study is an oncology-related randomized trial, but it does not meet core eligibility criteria: it is not a drug intervention trial and does not have a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia. PMID 38753328 · JAMA Netw Open · 2024-May-01 The record describes a comparative effectiveness analysis of patients from two prior randomized trials (AML02 and AML08). While it includes time-to-event outcomes (EFS) and drug interventions, it is a secondary analysis focusing on racial disparities and pharmacogenomics, not a primary report of a definitive Phase III/IIIb or Phase II/III randomized trial. The phase of the underlying trials is not explicitly stated in the abstract, and the analysis is post-hoc in nature.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC. PMID 38700864 · JAMA Netw Open · 2024-May-01 This record is a secondary comparative analysis of a clinical trial (IMpower132) and an observational cohort, not the original report of the trial's efficacy results. It is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating the effect of a mobile-based symptom monitoring system for improving physical function in patients with cancer during chemotherapy: study protocol for a multicentre randomised controlled trial. PMID 38692724 · BMJ Open · 2024-May-01 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The novel rapid formulation of intravenous dantrolene (NPJ5008) versus standard dantrolene (Dantrium®): A clinical part-randomised phase 1 study in healthy volunteers. PMID 38445365 · Eur J Anaesthesiol · 2024-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials. PMID 38412408 · J Clin Oncol · 2024-May-01 While the study is an oncology randomized trial with a time-to-event endpoint (OS) and includes drug therapy, the explicit trial phase (III/IIIb or II/III) is not established in the provided record. Furthermore, the primary intervention is a surgical procedure (PTR), not a standardized drug-containing regimen as the key randomized comparison, which does not meet the 'drug-containing intervention' requirement as specified for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Suitability of the MP1000 system for robot-assisted partial nephrectomy: a multicenter randomized controlled noninferiority trial. PMID 38349210 · Int J Surg · 2024-May-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized Prostate Cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA). PMID 38163520 · Int J Radiat Oncol Biol Phys · 2024-May-01 The study is a randomized, human oncology trial reporting a time-to-event endpoint (DFS), but it is ineligible because it does not meet the 'drug-containing intervention' criterion; the interventions are radiation-based (HDR-BT and EBRT). Additionally, the formal trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial. PMID 38161319 · Cancer · 2024-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT). PMID 37979707 · Int J Radiat Oncol Biol Phys · 2024-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase 3 Randomized Controlled Trial. PMID 37924987 · Int J Radiat Oncol Biol Phys · 2024-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A comparison of port-site infiltration with bupivacaine alone vs. bupivacaine plus dexemedetomidine after diagnostic staging laparoscopy. PMID 38783430 · J Pak Med Assoc · 2024-May 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
[The use of medical imaging as a therapeutic patient education tool in radiotherapy : a feasibility study]. PMID 38778656 · Rev Med Liege · 2024-May The record is a randomized controlled trial in oncology patients, but it is a feasibility study for an educational intervention using medical imaging, not a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. The endpoints are knowledge, anxiety, emotional distress, and depression scores, not time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A pilot randomised controlled trial of acceptance and commitment therapy for medication decision-making and quality of life in women with breast cancer: The ACTION trial. PMID 38752788 · Psychooncology · 2024-May The study is a randomized pilot trial for a Phase III trial feasibility, not a definitive Phase III or Phase II/III trial, and does not report a primary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, KM, or HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PMID 38728364 · PLoS Med · 2024-May Meets all eligibility criteria: oncology, human, randomized, phase III/definitive, time-to-event endpoint (PFS), drug intervention, and original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation. PMID 38723213 · JCO Clin Cancer Inform · 2024-May The record describes a retrospective, observational study using real-world data to emulate a target trial for treatment timing of allogeneic HSCT in hematologic neoplasms. It is not a randomized controlled trial, does not involve a drug-containing intervention, and does not report results from a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience. PMID 38718704 · ESMO Open · 2024-May The study is a randomized, prospective trial in oncology patients with a time-to-event endpoint (OS, bPFS). However, the primary intervention being evaluated is PET radiotracers (diagnostic imaging) for response assessment, not a therapeutic drug intervention. The abstract does not specify the trial phase, and it is not a Phase III or Phase II/III drug efficacy trial. The analysis of OS and PFS is secondary to the primary aim of evaluating PET performance, making it a secondary/observational analysis of prognostic markers, not a primary drug efficacy result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. PMID 38711253 · Hematol Oncol · 2024-May The study is an original, Phase 3b oncology trial with a drug intervention in humans, but it is not randomized and does not report a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effects of resistance exercise and leucine-enriched essential amino acid supplementation on muscle mass and physical function in post-gastrectomy patients: a pilot randomized controlled trial. PMID 38694013 · J Phys Ther Sci · 2024-May The study is a randomized, controlled, pilot trial in post-gastrectomy patients (oncology context) with a drug intervention (LEAA supplementation). However, it is explicitly a pilot trial (Phase II equivalent) and does not report a time-to-event efficacy endpoint; its primary endpoint is a continuous measure (change in muscle mass).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling. PMID 38680089 · Cancer Med · 2024-May The record describes a randomized trial of clofarabine in ALL. While it is oncology, human, randomized, drug-interventional, and reports original results, two key criteria are not met: 1) The trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata (deterministic review flagged 'phase3_evidence_unclear'). 2) The primary analysis presented is a multi-state model investigating intermediate events (going off-protocol, MRD negativity) and their transitions, not a standard primary time-to-event efficacy endpoint like OS, PFS, or EFS for the overall trial population. The abstract mentions EFS was the endpoint in the original report ('No improvement of event-free survival (EFS) was observed'), but this specific analysis deepens that with multi-state modeling, which is a secondary/exploratory analysis, not the primary Kaplan-Meier or HR result for the trial's main endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Contrast-enhanced Ultrasound Using Intradermal Microbubble Sulfur Hexafluoride in Non-invasive Axillary Staging in Breast Cancer: Are we Missing a Chance? PMID 38677765 · Anticancer Res · 2024-May The study is a non-randomized, single-arm Phase III trial evaluating a contrast-enhanced ultrasound procedure, not a drug intervention. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. Therefore, it does not meet the inclusion criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). PMID 38663168 · ESMO Open · 2024-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here? PMID 38649630 · Curr Treat Options Oncol · 2024-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. PMID 38621400 · Lancet Oncol · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial. PMID 38615472 · ESMO Open · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. PMID 38608691 · Lancet Oncol · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203. PMID 38595316 · Hematol Oncol · 2024-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy. PMID 38591703 · J Urol · 2024-May The record is a randomized, human, oncology trial with a drug intervention and a time-to-event primary endpoint. However, the provided metadata (title, abstract, publication types) does not explicitly establish that this is a Phase III/IIIb or Phase II/III trial. The deterministic review correctly flagged 'phase3_evidence_unclear'. Without explicit phase information in the record, the eligibility criterion for definitive phase is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study. PMID 38584069 · Clin Lung Cancer · 2024-May The record is a Phase 3 drug intervention trial in oncology. However, the title indicates it is a 'Brief Report' focusing on outcomes by PD-L1 expression subgroup, which is a post-hoc or secondary analysis, not a primary efficacy report of the randomized trial. Furthermore, there is no explicit signal in the title, abstract (missing), or metadata for a primary time-to-event efficacy endpoint, Kaplan-Meier plot, or hazard ratio, which are required for eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review. PMID 38582227 · Crit Rev Oncol Hematol · 2024-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Haemoblock hemostatic substance in reducing seroma formation post axillary lymph node dissection following breast conserving surgery. PMID 38578243 · World J Surg · 2024-May The study is a randomized, double-blind, placebo-controlled trial in human breast cancer patients, but it evaluates a hemostatic substance (Haemoblock) for reducing seroma after axillary dissection, not a systemic anti-cancer drug. The primary endpoint (time to drain removal) is a surgical complication endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Phase is not stated as Phase III/IIIb or Phase II/III. Therefore, it does not meet eligibility criteria for the oncology KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Inguinal Lymphadenectomy for Penile Cancer: An Interim Report from a Trial Comparing Open Versus Videoendoscopic Surgery Using a Within-patient Design. PMID 38558767 · Eur Urol Open Sci · 2024-May 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Clinical Trial Protocol for "Replace Cysto": Replacing Invasive Cystoscopy with Urine Testing for Non-muscle-invasive Bladder Cancer Surveillance-A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surveillance with Xpert Bladder Cancer Monitor or Bladder EpiCheck Urine Testing Versus Frequent Cystoscopy. PMID 38558761 · Eur Urol Open Sci · 2024-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial. PMID 38552544 · Lung Cancer · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: single-centre, non-inferiority, open-label, randomised, phase 3 trial. PMID 38550605 · Lancet Reg Health Southeast Asia · 2024-May The study is a randomized Phase 3 trial in human breast cancer with original results. However, it compares two radiotherapy schedules and does not involve a drug-containing intervention. The primary endpoints are acute toxicity and cosmetic outcome, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. PMID 38547774 · Eur J Cancer · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial. PMID 38538861 · Leukemia · 2024-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type confirmed 1 Figure · 6 Panel · risk visible
Intraoperative frozen section pathology of vaginal margin in radical hysterectomy on the prognosis and quality of life for patients with IB2-IIA2 cervical cancer: study protocol for a multicenter randomized controlled trial. PMID 38522951 · J Gynecol Oncol · 2024-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial. PMID 38513683 · Lancet Gastroenterol Hepatol · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Shenbai Granules for recurrent colorectal adenoma: A multicenter randomized controlled trial. PMID 38471368 · Phytomedicine · 2024-May The study is a randomized trial of a drug intervention for a human cancer precursor, but it does not meet the core criteria for the cohort: it is not for a malignant neoplasm (adenoma is benign), and its primary efficacy endpoint is not a time-to-event measure (it uses logistic regression on recurrence proportion).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A pragmatic randomized clinical trial of multilevel interventions to improve adherence to lung cancer screening (The Larch Study): Study protocol. PMID 38467273 · Contemp Clin Trials · 2024-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial. PMID 38457083 · Gastric Cancer · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial. PMID 38447379 · Eur J Cancer · 2024-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Re: Ivo I. de Vos II, Sebastiaan Remmers, Renée Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol 2024;85:74-81. PMID 38429126 · Eur Urol · 2024-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -